Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients. 2016

Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
Departments of aRadiation Oncology bHead and Neck Surgery, Tenon Hospital, HUEP, UPMC, Paris VI University, Paris, France.

The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077235 Vinorelbine A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. 5'-Nor-anhydrovinblastine,KW 2307,KW-2307,Navelbine,Vinorelbine Tartrate,5' Nor anhydrovinblastine,KW2307
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
November 2012, Anti-cancer drugs,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
January 2012, Acta oncologica (Stockholm, Sweden),
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
January 1999, Oncology,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
August 1998, American journal of clinical oncology,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
February 2023, Clinical cancer research : an official journal of the American Association for Cancer Research,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
September 2019, The Korean journal of internal medicine,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
October 2022, Scientific reports,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
January 2020, OncoTargets and therapy,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
December 2002, Head & neck,
Claire Barth, and Louise Naveau, and Emmanuel Touboul, and Sophie Périé, and Edith Bamogho, and Sophie Haberer-Guillerm, and Michel Schlienger, and Jean Lacau St Guily, and Florence Huguet
January 2021, Frontiers in oncology,
Copied contents to your clipboard!